Biologically Active Small Molecules

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

An IDH1 inhibitor.

An IDH1 inhibitor.

An IDH1 inhibitor.

An IDH1 inhibitor.

A tyrphostin that is a poor inhibitor of EGFRK (IC₅₀ = 450 &muM) and PDGFRK (IC₅₀ &gt 100 &muM) which has been found to inhibit the phosphorylation of ERK1 and ERK2 at 25-50 &muM blocks the production of TNF-&alpha,